COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase III, Randomized Study Of Nivolumab (OPDIVO) Plus AVD Or Brentuximab Vedotin (ADCETRIS) Plus AVD In Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Protocol No
SWOG-S1826-HL
Principal Investigator
Timothy Fenske
Phase
III
Summary
This study is being done to answer the following question: If we add the study drug nivolumab to standard chemotherapy will it extend the time without disease more than or less than if we add the study drug brentuximab vedotin to standard chemotherapy?
Description
Nivo plus AVD or BV plus AVD in newly diagnosed advanced HL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL